<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="author-highlights" id="ab0010">
 <title>Highlights</title>
 <p>
  <list list-type="simple" id="l0005">
   <list-item id="li0005">
    <label>•</label>
    <p id="p0005">COVID-19 RdRp shares 97% sequence identity to SARS.</p>
   </list-item>
   <list-item id="li0010">
    <label>•</label>
    <p id="p0010">COVID-19 RdRp model is built to study inhibitors.</p>
   </list-item>
   <list-item id="li0015">
    <label>•</label>
    <p id="p0015">Sofosbuvir, Ribavirin, and Remdesivir can bind to COVID-19 RdRp.</p>
   </list-item>
   <list-item id="li0020">
    <label>•</label>
    <p id="p0020">IDX-184 may be used as a seed to obtain a potent inhibitor specific against COVID-19 RdRp.</p>
   </list-item>
  </list>
 </p>
</abstract>
